To the Editor: Landoni et al. (May 25 issue)1 examined levosimendan administration versus placebo for patients requiring hemodynamic support after cardiac surgery. In their trial (Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients: A Multicenter Randomized Controlled Trial [CHEETAH]), they found no significant difference in mortality between the two groups. The investigators aimed to include patients with shock after cardiac surgery and cardiopulmonary bypass. However, many of the patients were likely to have distributive shock (i.e., 57.7% received epinephrine, 45.3% norepinephrine, and 15.2% dopamine) rather than cardiogenic shock (28.3% received dobutamine and 12.5% enoximone) (Table S5 in the . . .

中文翻译：

---

左西孟旦心脏外科

致编辑：Landoni等。（5月25日发行）1对心脏手术后需要血流动力学支持的患者进行了左西孟旦与安慰剂的对比研究。在他们的试验中（左西孟旦降低高风险心脏手术患者的死亡率：多中心随机对照试验[CHEETAH]），他们发现两组之间的死亡率没有显着差异。研究人员的目的是包括心脏手术和体外循环后休克的患者。然而，许多患者可能会发生分配性休克（即接受肾上腺素的有57.7％，去甲肾上腺素的有45.3％，多巴胺为15.2％），而不是心源性休克（有28.3％的多巴酚丁胺和12.5％的依诺酮）（见表S5）。 。